The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis.

ABSTRACT:

Purpose

Glucagon-like peptide-1 (GLP-1) receptor agonists have shown potential in managing eating disorders (EDs). Recent studies highlight their effects on pathophysiological pathways, indicating their therapeutic promise, particularly for binge eating disorder (BED). This systematic review evaluates the therapeutic effects of GLP-1 agonists on BED, focusing on weight management and eating behaviors.

Methods

A systematic search of PubMed, Scopus, Web of Science, and the Cochrane Library, along with manual searches, identified studies assessing GLP-1 agonists in BED patients up to November 8, 2024. Observational studies and clinical trials meeting inclusion criteria were analyzed.

Results

Five studies (182 participants) were included. Patients receiving GLP-1 agonists

SUBMITTER: Radkhah H 

PROVIDER: S-EPMC11787217 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature